ImmunityBio and Japan BCG Laboratory Partner to Advance FDA Pathway for Tokyo-172 BCG in High-Grade NMIBC

Positive Phase III readout of National Cancer Institute sponsored SWOG S1602 randomized clinical trial demonstrating non-inferior efficacy of the Tok...

May 18, 2026 | Monday | News
CellDx-Tissue Receives US FDA Clearance, Strengthening Datar Cancer Genetics’ Global Precision Oncology and Biomarker Development Capabilities

Clearance Recognises CellDx-Tissue's Dual-Analyte DNA and RNA Workflow Across 517 Cancer-Associated Genes, with ALK, RET and ROS1 Fusion Calls on RNA-Lev...

May 18, 2026 | Monday | News
Gyre Therapeutics Achieves Key Regulatory Milestone as China Accepts NDA for F351 Liver Fibrosis Treatment

Gyre Therapeutics, Inc. (“Gyre”, “Gyre Therapeutics” or the “Company”) (Nasdaq: GYRE), an innovative, commercial-stag...

May 14, 2026 | Thursday | News
Dark Horse Consulting Group and KunTuo Forge Strategic Alliance to Accelerate Biotherapeutic Clinical Trials in China

Dark Horse Consulting Group, a leading strategic and operational consulting enterprise in the field of biological therapy (hereinafter referred to as " DHC...

May 13, 2026 | Wednesday | News
MacroGenics Sells Maryland Biologics Manufacturing Operations to Bora Pharmaceuticals for $122.5 Million

•MacroGenics to receive $122.5 million upfront payment from Bora upon closing•Transaction includes transfer of manufacturing site, CDMO operati...

May 13, 2026 | Wednesday | News
China Grants Breakthrough Therapy Designation to NHWD-870 HCI for Advanced NUT Carcinoma

Recently, the novel oral BET inhibitor NHWD-870 HCI, independently developed by Zhejiang Wenda Pharmaceutical Technology Co., Ltd., officially recei...

May 12, 2026 | Tuesday | News
Nxera Launches New GPCR-Focused Spinout to Advance NxWave™ Program Through Global Clinical Development

New company (“NewCo”) co-founded by Nxera with a syndicate of leading healthcare and life sciences-focused investment firms. In return for...

May 12, 2026 | Tuesday | News
Hongene Biotech Supports SiranBio’s Dual-Target siRNA Program SA1211 with End-to-End CDMO Capabilities

Hongene Biotech Corporation today announced its support of SiranBio’s SA1211 program, a dual-target siRNA candidate for chronic hepatitis B, unders...

May 07, 2026 | Thursday | News
FreeMind Investments and Daewoong Pharmaceutical Invest in General Proximity to Advance Induced Proximity Therapeutics

FreeMind Investments (FMI), a venture capital fund launched in partnership between FreeMind Group and Daewoong Pharmaceutical Co., Ltd., announced its in...

May 06, 2026 | Wednesday | News
AGC Biologics Expands Manufacturing Partnership with Novelty Nobility for Bispecific Antibody NN4101

Successful partnership continues as bispecific antibody candidate moves to GMP manufacturing; project highlights Japan's advanced capabilities in bioproc...

May 05, 2026 | Tuesday | News
AGC Biologics Expands Manufacturing Partnership with Novelty Nobility for Bispecific Antibody NN4101

Successful partnership continues as bispecific antibody candidate moves to GMP manufacturing; project highlights Japan's advanced capabilities in bioproc...

May 05, 2026 | Tuesday | News
Claruvis Secures China Approval for Retoxin®, the World’s First Recombinant Botulinum Toxin Type A

Chongqing Claruvis Pharmaceutical Co., Ltd. recently announced that the China's National Medical Products Administration (NMPA) has approved its Retoxin&...

May 01, 2026 | Friday | News
Taiho Oncology, Inc. Advances First ADC Candidate ARC-02 into Phase 1 Following U.S. Food and Drug Administration IND Clearance

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administra...

April 30, 2026 | Thursday | News
Samsung Bioepis and ATLATL Innovation Center Sign MoU to Advance Open Innovation in Asia-Pacific Biotech

Samsung Bioepis Co., Ltd. and ATLATL Innovation Center (hereinafter referred to as "ATLATL"), global innovation platform for life science research and de...

April 30, 2026 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close